Illumina News and Research

RSS

New federal funding enables researchers to unravel how humans develop cancers

A Simon Fraser University scientist working at one of Canada's first epigenomics mapping centres says new federal funding will accelerate researchers' ability to unravel how we develop some of the most common life threatening cancers.

26 Oct 2012

HDL may protect against abdominal aortic aneurysm

High levels of high-density lipoprotein cholesterol inhibit the formation of abdominal aortic aneurysm, findings from experimental mouse models suggest.

2 Oct 2012

Illumina launches new RNA sequencing kits

Illumina today introduced TruSeq Stranded mRNA and Total RNA Sample Preparation Kits for RNA sequencing. The new reagent kits enable researchers to quickly and easily conduct gene expression studies that provide a complete view of the transcriptome, even from low-quality RNA samples, such as formalin-fixed, paraffin-embedded (FFPE) samples.

From Illumina, Inc. 19 Sep 2012

Researchers hold new implications for pathogenesis of myotonic dystrophy

An important breakthrough could help in the fight against myotonic dystrophy. The discovery, recently published in the prestigious scientific journal Cell, results from an international collaboration between researchers at the IRCM, the Massachusetts Institute of Technology (MIT), the University of Southern California and Illumina.

13 Sep 2012

Eurofins MWG Operon acquires Illumina HiSeq 2500 and MiSeq sequencers

Eurofins MWG Operon, one of the pioneers and key providers of next generation sequencing (NGS), has added an Illumina HiSeq 2500 and an Illumina MiSeq sequencer to its fleet of NGS sequencers.

From Illumina, Inc. 5 Sep 2012

U.S. District Court rules in favor of Illumina over Helicos lawsuit

Illumina, Inc. announced today that District Judge Sue L. Robinson of the U.S. District Court for the District of Delaware granted Illumina's motion for summary judgment of invalidity of U.S. Patent No. 7,593,109, a patent asserted by Helicos BioSciences Corporation in a lawsuit filed against Illumina in October 2010. Judge Robinson ruled that the '109 patent was invalid for inadequate written description.

From Illumina, Inc. 30 Aug 2012

Novel genomic sequencing method can help conduct in-depth analysis of single cells

Only by viewing a Georges Seurat painting at close range can you appreciate the hidden complexities of pointillism - small, distinct dots of color applied to form an image from a distance. Similarly, biologists and geneticists have long sought to analyze profiles of genes at the single cell level but technology limitations have only allowed a view from afar.

23 Jul 2012

Illumina sues IBS and Qiagen for infringement of three patents

Illumina, Inc. today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware.

From Illumina, Inc. 23 Jul 2012

Illumina launches new kits for targeted resequencing studies

Illumina, Inc. today introduced Nextera Exome and Custom Enrichment kits, the Company's latest targeted resequencing solutions offering sample preparation and enrichment in a single, integrated workflow.

From Illumina, Inc. 17 Jul 2012

Illumina launches RapidTrack WGS service

Illumina, Inc. today launched the RapidTrack Whole Genome Sequencing Service, a new offering in its FastTrack Sequencing Services operation that delivers a whole human genome in less than two weeks.

From Illumina, Inc. 21 Jun 2012

Comprehensive data analysis and interpretation offered to customers as a result of collaboration between ATLAS Biolabs and Ingenuity systems

ATLAS Biolabs and Ingenuity® Systems have signed a collaboration agreement that gives ATLAS Biolabs’ customers the option to analyse and interpret their study data using Ingenuity solutions.

19 Jun 2012

Illumina's new patent infringement suit targets Complete Genomics' cPal read technology

Illumina (NASDAQ:ILMN) announced today that the company has filed an additional patent infringement suit against Complete Genomics, Inc. Illumina is seeking all available remedies, including injunctive relief.

From Illumina, Inc. 18 Jun 2012

Illumina launches Nextera XT DNA Sample Preparation Kits

Illumina today introduced the Nextera XT DNA Sample Preparation Kit, the easiest way for researchers to prepare and sequence small genomes, PCR amplicons, and plasmids.

From Illumina, Inc. 1 Jun 2012

QCMG establishes Illumina technology as core sequencing platform

Illumina today announced that the Queensland Centre for Medical Genomics (QCMG), home of Australia's International Cancer Genomics Consortium program, has established Illumina technology as its core sequencing platform in an expanded facility.

30 May 2012

Helico reaches patent litigation settlement with Pacific Biosciences

Helicos BioSciences Corporation announced today that it has settled its patent infringement litigation against Pacific Biosciences, Inc.

15 May 2012

Scientists discover new type of dynamic change in human stem cells

A team led by scientists at The Scripps Research Institute and the University of California (UC) San Diego has discovered a new type of dynamic change in human stem cells.

4 May 2012

LifeCodexx completes PraenaTest clinical study on trisomy 21

LifeCodexx today announced the successful completion of the clinical validation study of its noninvasive test method for the detection of fetal trisomy 21 from maternal blood using Next Generation sequencing.

2 May 2012

ISS recommends Illumina shareholders to vote against Roche's nominees

Roche released the following statement in response to a report issued by Institutional Shareholder Services recommending that shareholders of Illumina, Inc. vote against the election of Roche's independent director nominees to Illumina's Board of Directors.

From Illumina, Inc. 7 Apr 2012

RainDance introduces new panel for cancer mutation screening

RainDance Technologies, Inc., the Digital Biology company, today announced the worldwide availability of its new panel for cancer mutation screening research using any next-generation sequencing (NGS) system.

2 Apr 2012

Roche announces increase in offer price for outstanding Illumina shares

Roche announced today that it has increased its offer price for all outstanding publicly-held shares of Illumina, Inc. to US$ 51.00 per share in cash.

From Illumina, Inc. 29 Mar 2012